Core Viewpoint - The internal control evaluation report of Everbright Securities indicates that as of December 31, 2024, the company maintains effective internal controls over financial reporting and has not identified any significant deficiencies in both financial and non-financial internal controls [2][15]. Internal Control Evaluation Conclusion - The company has confirmed the effectiveness of its internal controls, with no significant deficiencies identified in financial reporting [2][15]. - There are no significant deficiencies in non-financial reporting internal controls as of the evaluation date [2][15]. - No factors affecting the effectiveness of internal controls have occurred between the evaluation date and the report issuance date [2][15]. Internal Control Evaluation Work Situation Evaluation Scope - The evaluation covered all major units, businesses, and high-risk areas, including subsidiaries and various business lines such as investment banking, asset management, and securities trading [3][4]. Internal Control System Construction - The company has implemented high standards for internal control system construction, focusing on risk prevention and compliance with regulatory requirements [4][5]. - Continuous improvement of internal control mechanisms has been emphasized, including the establishment of a multi-layered supervision system [5][6]. Key Business and High-Risk Area Control Measures - Investment Banking: The company has optimized its internal control management system, establishing a three-line defense mechanism to manage risks effectively [6][7]. - Securities Proprietary Trading: A centralized decision-making mechanism has been established to ensure compliance with internal control standards [7][8]. - Asset Management: A comprehensive internal control system has been developed to manage investment processes and mitigate risks [8][9]. - Futures Business: The governance structure has been improved, focusing on compliance and risk management [9][10]. - Credit Business: A robust internal control mechanism has been established to manage various risks associated with credit operations [10][11]. - Wealth Management: The company has implemented various measures to ensure compliance and effective management of wealth management activities [11][12]. - Financial Innovation: Continuous optimization of internal control mechanisms for innovative financial products has been prioritized [12][13]. - Overseas Business: The governance processes for overseas operations have been enhanced to adapt to regulatory changes [13][14]. - Subsidiary Management: A vertical and transparent management mechanism has been established to mitigate risks associated with subsidiaries [14][15]. Other Internal Control Related Major Matters - The company has not identified any significant deficiencies in internal controls in the previous year, and all identified general deficiencies have been rectified [15][16]. - An independent audit by KPMG confirmed the effectiveness of the company's internal controls as of December 31, 2024 [15][16].

公司代码：600938 公司简称：中国海油 中国海洋石油有限公司 中国海洋石油有限公司全体股东： 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提 根据《企业内部控制基本规范》及其配套指引的规定和Committee of Sponsoring Organization （以下简称"COSO委员会"）制定的内部控制框架（以下简称"企业内部控制规范体系"），结合中国海 洋石油有限公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基 础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要说明 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降 低， 公司董事会的职责是确保本公司建立和维持适当且有效的风险管理和内控控制系统、审视其有效 性、并确保公司对内部控制评价报告进行如实披露。在公司董事会监督下，公司管理层负责建立健全和 有效实施内部控制，并对有效性做出自检查和评价。公 ...

Core Viewpoint - The internal control evaluation report of China Merchants Energy Transportation Co., Ltd. indicates that the company has maintained effective internal controls over financial reporting and has not identified any significant deficiencies as of December 31, 2024 [2][8]. Internal Control Evaluation Conclusion - The company has confirmed that there are no significant deficiencies in financial reporting internal controls [2][8]. - There are no significant deficiencies identified in non-financial reporting internal controls [2][8]. - No factors affecting the effectiveness of internal control evaluations have occurred between the evaluation date and the report issuance date [2][8]. Internal Control Evaluation Work - The evaluation scope included major units, businesses, and high-risk areas based on a risk-oriented principle [3][4]. - The total assets and total operating income of the evaluated units accounted for 100% of the company's consolidated financial statements [3][4]. - The company has identified and assessed internal control deficiencies across 118 primary processes, 289 secondary processes, and 690 tertiary processes, ensuring timely and effective rectification [3][4][10]. Internal Control Deficiency Recognition and Rectification - The company has identified a total of 27 internal control deficiencies through self-assessment in 2024 [8][10]. - A total of 34 internal control deficiencies have been rectified, including 21 from previous years and 13 newly identified in 2024 [8][10]. - The company will continue to monitor and follow up on unresolved internal control deficiencies to enhance the internal control system [8][10]. Future Internal Control Management - The company plans to enhance the internal control system's coverage and quality, focusing on the completeness and execution of the internal control framework [10][11]. - There will be an emphasis on risk identification and assessment to proactively manage potential risks [11][12]. - The company aims to improve the digitalization of internal control management, particularly in credit risk management, to ensure automated and intelligent execution of control measures [12].

Core Viewpoint - The internal control evaluation report of Rongchang Biopharmaceuticals indicates that the company has maintained effective internal controls over financial reporting and has not identified any significant deficiencies in both financial and non-financial reporting [1][2]. Internal Control Objectives - The objectives of the internal control system are to ensure legal compliance in management, asset security, and the accuracy of financial reporting, thereby enhancing operational efficiency and supporting strategic development [2]. Internal Control Evaluation Conclusion - The company has concluded that there are no significant deficiencies in financial reporting internal controls as of the evaluation date [2][3]. - There are also no significant deficiencies identified in non-financial reporting internal controls [2][3]. - No factors affecting the evaluation conclusion have occurred between the evaluation date and the report issuance date [2]. Internal Control Evaluation Scope - The evaluation covered all major units, businesses, and high-risk areas, with 100% of the total assets and revenues included in the evaluation scope [3]. Internal Control Evaluation Standards - The company has established quantitative and qualitative standards for identifying internal control deficiencies, maintaining consistency with previous years [4][6]. - Quantitative standards for financial reporting deficiencies include thresholds based on asset and revenue misstatements [4][6]. Internal Control Deficiencies and Remediation - During the reporting period, the company identified some general deficiencies in financial reporting internal controls, which have been rectified without impacting the overall control objectives [7]. - Similarly, general deficiencies in non-financial reporting internal controls were also identified and addressed [7]. Future Plans - The company plans to further enhance its internal control system and strengthen internal supervision to mitigate various risks and promote healthy development in 2025 [7].

Core Viewpoint - The Audit Committee of Rongchang Biopharmaceutical (Yantai) Co., Ltd. has diligently fulfilled its supervisory responsibilities for the year 2024, ensuring compliance with relevant regulations and maintaining effective internal controls [1][4]. Group 1: Audit Committee Overview - The Audit Committee consists of three members, including independent director Ma Lan and director Wang Liqiang, with accounting professional Hao Xianjing serving as the chairperson [1]. - During the reporting period, the Audit Committee held five meetings, with full attendance from all members [1]. Group 2: Key Activities of the Audit Committee - The committee supervised and evaluated the external audit firm, Ernst & Young, ensuring that it adhered to independent and objective auditing standards [1][3]. - The committee guided the internal audit work, reviewing the internal audit plan and confirming its feasibility, while ensuring compliance with the audit plan [2][3]. - The committee reviewed the company's financial reports, concluding that they were true, accurate, and complete, with no significant fraud or misstatements detected [3]. - The committee monitored and assessed the effectiveness of the company's risk management and internal control systems, confirming that there were no major deficiencies [3][4]. - The committee facilitated communication between management, internal audit, and external auditors, enhancing the efficiency of the audit process [4]. Group 3: Overall Evaluation - The Audit Committee has effectively fulfilled its responsibilities in accordance with relevant laws, regulations, and the company's articles of association, promoting sound operations and safeguarding the rights of shareholders [4].

内部控制审计报告 杭州解百集团股份有限公司 容诚审字2025230Z1216 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 内部控制审计报告 TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚审字2025230Z1216 号 杭州解百集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了杭州解百集团股份有限公司（以下简称"杭州解百"）2024 年 12 月 31 日的财务报告内部控制的有效性。 ...

南京熊猫电子股份有限公司 事，本人根据《公司法》《证券法》《上市公司独立董事管理办法》等法律法规 和《南京熊猫电子股份有限公司章程》（以下简称"《公司章程》"）《南京熊 猫电子股份有限公司独立董事制度》等有关规定，勤勉、忠实地履行职责，积极、 认真地出席会议，谨慎、恰当地行使权利，中肯、客观地发表意见，充分发挥经 验及专长，在公司规范运作和重大经营决策等方面做了许多工作，切实维护了公 司整体和全体股东利益。现将 2024 年度履职情况报告如下： 一、独立董事的基本情况 根据中国证监会、上海证券交易所、香港联交所等有关规定，本人确认符合 独立性的要求，不存在影响独立性的情况，并向公司发出关于独立性的自查报告。 二、独立董事年度履职情况 （一）董事会及股东会出席情况 参加股 参加董事会情况 东会情 况 本年应参 亲自 以通讯 是否连续两 出席股 委托出 缺席次 董事姓名 加董事会 出席 方式参 次未亲自参 东会的 席次数 数 次数 次数 加次数 加会议 次数 朱维驯 16 16 0 0 0 否 3 作为公司独立董事，在相关会议召开前，本人详细审阅了会议文件和做出决 策所需要的资料。会上认真审议每个议题，积极参与讨 ...

上海九百股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了上海九百股份有限公司(以下简称九百股份)2024年12月31日的财务报告 内部控制的有效性。 上海九百股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 内部控制审计报告 汇会审20252603号 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是九百股份 董事会的责任。 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No. ...

Core Viewpoint - The report indicates that Zhejiang Weihua New Materials Co., Ltd. has undergone a thorough on-site inspection by CITIC Securities, confirming that the company operates in compliance with relevant regulations and has a well-structured governance system, although it faces challenges in profitability due to market conditions [1][6]. Summary by Sections On-site Inspection Overview - CITIC Securities conducted an on-site inspection of Zhejiang Weihua New Materials on March 20, 2025, as part of its ongoing supervisory responsibilities [1]. Company Governance and Internal Control - The inspection found that the company's governance structure and internal control systems are complete and compliant, with effective execution of internal controls and proper functioning of the board and committees [2]. Information Disclosure - The company’s disclosure documents were found to be accurate and complete, with no discrepancies noted between disclosed information and actual circumstances [3]. Independence and Related Party Transactions - The company has established measures to prevent the misuse of funds by controlling shareholders and related parties, ensuring that there are no violations regarding the use of company resources [4]. Use of Raised Funds - The inspection confirmed that the management of raised funds complies with regulations, with no evidence of misappropriation by controlling shareholders or unauthorized changes in fund usage [5]. Related Transactions and Major Investments - The company has adhered to regulations regarding related transactions, external guarantees, and significant investments, with no major violations or harm to minority shareholders identified [5]. Operating Conditions - The company’s operational model remains stable; however, it is experiencing significant price declines in its main products due to industry cyclicality and increased competition, impacting profitability [6]. Recommendations - The report advises the company to focus on its core business and maintain prudent operations while addressing the reasons for the anticipated decline in performance [6]. Reporting Obligations - The inspection concluded that there are no matters that require reporting to the China Securities Regulatory Commission or the Shanghai Stock Exchange [6]. Cooperation with Intermediaries - The company provided active cooperation during the inspection, facilitating the process without the involvement of other intermediaries [6]. Conclusion of the Inspection - Overall, the inspection affirmed that the company’s operations align with the requirements of the Shanghai Stock Exchange and relevant laws and regulations [6].

福达股份: 福达股份2024年内部控制评价报告 公司代码：603166 公司简称：福达股份 桂林福达股份有限公司 桂林福达股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况 ...